

Independent Auditor's Review Report on Standalone unaudited financial results of Advanced Enzyme Technologies Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.


To The Board of Directors of Advanced Enzyme Technologies Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Advanced Enzyme Technologies Limited (hereinafter referred to as 'the Company') for the quarter ended September 30, 2025 and the year to-date results for the period from April 01, 2025 to September 30, 2025 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No.105047W



Amrish Vaidya
Partner

Membership No.: 101739

UDIN:25101739BM1KMZ2105



Place: Mumbai

Date: November 12, 2025

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.


Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Statement of unaudited standalone financial results for the quarter and six months ended 30 September 2025

(Rs in Million except per share data)

	Particulars	Quarter ended			Six months ended		Year ended
		30-Sep-25 Unaudited	30-Jun-25 Unaudited	30-Sep-24 Unaudited	30-Sep-25 Unaudited	30-Sep-24 Unaudited	31-Mar-25 Audited
1	Revenue from operations	1,157.48	1,250.24	773.78	2,407.72	1,633.35	3,514.11
2	Other Income	30.79	538.52	16.55	569.31	555.31	614.90
3	Total Income (1+2)	1,188.27	1,788.76	790.33	2,977.03	2,188.66	4,129.01
4	Expenses						
(a)	Cost of materials consumed	483.24	518.99	371.72	1,002.23	747.52	1,488.00
(b)	Purchases of stock-in-trade	-	-	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(22.73)	43.56	(80.62)	20.83	(142.20)	(64.67)
(d)	Employee benefits expense (refer note iii)	160.62	162.07	139.47	322.69	281.37	560.35
(e)	Finance costs (including exchange difference)	0.49	0.53	0.76	1.02	0.98	2.36
(f)	Depreciation and amortisation expense	30.02	29.29	27.84	59.31	54.03	114.05
(g)	Other expenses	240.44	220.36	207.95	460.80	402.19	823.64
	Total expenses	892.08	974.80	667.12	1,866.88	1,343.89	2,923.73
5	Profit before exceptional item and tax (3-4)	296.19	813.96	123.21	1,110.15	844.77	1,205.28
6	Exceptional item	-	-	-	-	-	-
7	Profit before tax (5-6)	296.19	813.96	123.21	1,110.15	844.77	1,205.28
8	Tax expense						
	Current tax	72.83	74.41	30.66	147.24	80.12	168.86
	Deferred tax charge/(credit)	0.54	(0.26)	1.29	0.28	2.83	12.22
	Total tax expense	73.37	74.15	31.95	147.52	82.95	181.08
9	Net profit for the period (7-8)	222.82	739.81	91.26	962.63	761.82	1,024.20
10	Other comprehensive income						
A (i)	Items that will not be reclassified to Profit or Loss						
	Remeasurements of defined benefit liability/(asset)	-	-	-	-	-	(4.60)
(ii)	Income tax related to items that will not be reclassified to Profit or Loss	-	-	-	-	-	1.16
B (i)	Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
(ii)	Income tax related to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	Total Other comprehensive income	-	-	-	-	-	(3.44)
11	Total comprehensive income (9+10)	222.82	739.81	91.26	962.63	761.82	1,020.76
12	Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.76	223.76	223.65	223.76	223.65	223.76
13	Other equity						6,069.65
14	Earnings Per Share of ₹ 2 each (not annualized)						
(a)	₹ (Basic)	1.99	6.61	0.82	8.60	6.82	9.16
(b)	₹ (Diluted)	1.99	6.61	0.81	8.59	6.80	9.15



W. W. Karm

Statement of standalone assets and liabilities

		(₹ in million)	
Particulars		As at 30-Sep-25 Unaudited	As at 31-Mar-25 Audited
I. ASSETS			
(1) Non-current assets			
(a) Property, Plant and Equipment		1,468.65	1,508.82
(b) Capital work-in-progress		309.54	207.35
(c) Other Intangible assets		54.58	56.18
(d) Intangible assets under development		0.22	0.17
(e) Financial Assets			
(i) Investments			
- Investment in subsidiaries		2,540.81	2,536.50
- other investment		0.62	0.62
(ii) Loans		0.06	0.65
(iii) Other financial assets		23.65	79.26
(f) Income tax asset (net)		179.88	160.00
(g) Other non-current assets		35.49	14.77
Total non-current assets		4,613.50	4,564.32
(2) Current Assets			
(a) Inventories		1,026.08	1,014.50
(b) Financial Assets			
(i) Investments		552.74	366.52
(ii) Trade receivables		1,025.16	781.69
(iii) Cash and cash equivalents		74.55	56.04
(iv) Bank balances other than (iii) above		6.36	2.28
(v) Loans		1.54	0.26
(vi) Other financial assets		111.58	48.81
(c) Other current assets		82.95	51.89
Total current assets		2,880.96	2,321.99
Total assets		7,494.46	6,886.31
II. EQUITY AND LIABILITIES			
(1) Equity			
(a) Equity share capital		223.76	223.76
(b) Other equity		6,486.77	6,069.65
Total equity		6,710.53	6,293.41
(2) Non-current liabilities			
(a) Financial liabilities			
(i) Lease liability		15.25	19.69
(b) Provisions		12.30	13.27
(c) Deferred tax liabilities (net)		118.28	118.00
Total non-current liabilities		145.83	150.96
(3) Current liabilities			
(a) Financial liabilities			
(i) Lease liability		8.54	7.95
(ii) Trade payables			
a) total outstanding dues of micro enterprises and small enterprises		22.07	33.30
b) total outstanding dues of creditors other than micro enterprises and small enterprises		353.60	193.46
(iii) Other financial Liabilities		149.14	134.89
(b) Other current liabilities		74.35	39.13
(c) Provisions		27.47	30.29
(d) Current tax liabilities (net)		2.93	2.92
Total current liabilities		638.10	441.94
Total equity and liabilities		7,494.46	6,886.31



W. W. K. K. K.



Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

STATEMENT OF STANDALONE CASH FLOW

	For six months ended 30 September 2025 Rs. in million Unaudited	For six months ended 30 September 2024 Rs. in million Unaudited
A. Cash flows from operating activities		
Profit before tax	1,110.15	844.77
	<u>1,110.15</u>	<u>844.77</u>
Adjustments for non-cash transactions		
Depreciation and amortization expense	59.31	54.03
(Profit) / Loss on sale of property, plant and equipment	0.19	(0.42)
Bad debts written off	0.10	0.17
Provision for doubtful trade receivables provided / (written back)	(5.38)	2.50
Employee stock compensation expense	25.25	18.28
Excess provision written back	0.05	(1.98)
Sundry balances written (back) (net)	0.02	(0.04)
Unrealized foreign exchange (gain)	(8.08)	(1.22)
Fair value adjustment on investments	(28.15)	(18.24)
	<u>1,153.46</u>	<u>897.85</u>
Items considered separately		
Interest income	(4.04)	(6.39)
Interest expenses	1.02	0.98
Dividend income	(535.41)	(528.06)
Operating profit before working capital changes	<u>615.03</u>	<u>364.38</u>
Adjustments for working capital changes		
(Increase) / Decrease in Other non-current financial assets	0.01	(1.27)
(Increase) / Decrease in other non-current assets	1.06	(0.16)
(Increase) / Decrease in inventories	(11.58)	(184.15)
(Increase) / Decrease in trade receivables	(229.71)	68.85
(Increase) / Decrease in Current loans	(1.28)	0.06
(Increase) / Decrease in other current financial assets	(59.25)	40.84
(Increase) / Decrease in Other current assets	(31.06)	(19.03)
(Decrease) / Increase in provisions	(3.76)	(9.02)
(Decrease) / Increase in trade payables	148.43	58.41
(Decrease) / Increase in other current financial liabilities	11.55	0.99
(Decrease) / Increase in other current liabilities	35.22	48.87
Cash generated from operating activities	<u>474.66</u>	<u>368.77</u>
Income taxes paid (net)	(167.14)	(180.19)
Net cash generated from operating activities	<u>307.52</u>	<u>188.58</u>
B. Cash flows from investing activities		
Purchase of property, plant and equipment (tangible assets)	(138.33)	(136.04)
Proceeds from sale of property, plant and equipment	0.14	0.98
Purchase of intangible assets (net of refunds)	(1.69)	(0.85)
Purchase of non-current investments	(0.50)	-
(Purchase) / Proceeds from sale of current investments (net)	(158.07)	43.90
Interest received	1.11	3.98
Dividend received	535.41	528.06
(Increase) / Decrease in bank deposits with maturity more than 3 months but less than 12 months	(3.23)	0.30
(Increase) / Decrease in bank deposits with maturity of more than 12 months #	55.60	-
Net cash generated in investing activities	<u>290.44</u>	<u>440.33</u>
C. Cash flows from financing activities		
Proceeds from issue of share capital including securities premium	7.21	3.70
Repayment of short-term borrowings (net) #	0.00	0.00
Interest paid	(0.00)	(0.02)
Payment of Lease liabilities	(4.88)	(4.69)
Dividends paid	(581.78)	(570.30)
Net cash (used in) financing activities	<u>(579.45)</u>	<u>(571.31)</u>
Net (decrease) / increase in cash and cash equivalents (A+B+C)	<u>18.51</u>	<u>57.60</u>
Cash and cash equivalents as at the beginning of the period	56.04	14.95
Cash and cash equivalents as at the end of the period	<u>74.55</u>	<u>72.55</u>
Composition of cash and cash equivalents		
Cash in hand	0.50	0.42
Balance with banks :		
Current account	70.83	31.93
Fixed deposit account (with maturity less than 3 months)	3.22	40.20
	<u>74.55</u>	<u>72.55</u>

Figures are below Rs 0.01 Million, hence disclosed as Rs 0.00



W. W. Katre

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Notes:

(i) The above standalone financial results of Advanced Enzyme Technologies Limited ('the Company') were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 12 November 2025. The above results have been subjected to 'Limited Review' by the statutory auditors of the Company and they have expressed an unmodified conclusion. The limited review report will be filed with stock exchanges and will be available on the Company's website. The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies in India.

(ii) The Company operates only in one business segment viz. 'manufacturing and sales of enzymes'.

(iii) The Shareholders at its Annual General meeting held on 19 August 2022 approved the Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") of the Company and its extension to the subsidiaries of the Company. National Stock Exchange of India Limited and BSE Limited (Stock Exchanges) vide their letter/e-letter dated 06 October 2022 and 18 October 2022 respectively granted its 'In-Principle' approval for listing of 2,500,000 Equity Shares of Rs. 2 each which may arise out of exercise of Options as and when exercised from time to time subject to the prescribed conditions. The Company has granted 576,000 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 12 August 2023, approved by Nomination and Remuneration Committee of the Board. The Company has further granted 512,500 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 27 March 2025, approved by Nomination and Remuneration Committee of the Board.

(iv) The Company has allotted 57,075 equity shares during the year ended 31 March 2025 to employees under the 'Employee Stock Option Scheme 2022' ("ESOP Scheme 2022").

(v) On 19 December 2024, the Company invested Rs 478.18 million in Advanced Enzymes Europe B.V. ("AEEBV") (wholly owned subsidiary) by way of subscription to 3,623,163 equity shares. The value per equity share is EUR 1.48 and the face value of EUR 1 per share. Pursuant to this conversion, the Company now holds 7,900,000 equity share of AEEBV and the Company continues to be 100% shareholder of AEEBV.

(vi) The final dividend for the financial year 2024-25 of Rs 1.20/- per equity share is paid on 5 August 2025 after approval of the shareholders of the Company in its Annual General Meeting held on 30 July 2025.

(vii) The Company has incorporated a new wholly owned subsidiary by name of Advanced Nutrazyme Private Limited ("ANPL"), the subsidiary received its certificate of incorporation on 4 July 2025. ANPL will be engaged in the business of sales and distribution of the Company's Nutrition and Wellness range of products.

(viii) Previous year / period amounts have been regrouped / reclassified wherever necessary.



By Order of the Board of Directors
For Advanced Enzyme Technologies Limited
CIN: L24200MH1989PLC051018

M. M. Kabra

M. M. Kabra
Wholetime Director
DIN : 00148294

Place: Thane

Dated: 12 November 2025